



Signs and Symptoms in Metabolic Diseases

Dr. Engin KÖSE

Ankara University Faculty of Medicine



Pediatric Metabolism

Inborn Errors of Metabolism




Sir Archibald Garrod,
around 1910

- Archibald Garrod
- 1908
- Anormal biochemical reaction
- Autosomal recessive inheritance




Inborn Errors of Metabolism

- Rare disease
- But when considered cumulatively, its frequency:
 - 1:4000-5000
 - Consanguineous marriage frequency !!!!!
 - %75 Autosomal recessive inheritance




Bölgelere göre akraba evliliği




Inborn Errors of Metabolism

- Pathological pictures caused by genetic defects in the enzyme or carrier proteins involved in the synthesis or degradation of proteins, carbohydrates and fatty acids



Inborn Errors of Metabolism

- The required specific end product cannot be produced
- Precursors, indicative of the defective enzyme, accumulate and may show toxic effects
- Activity increases in normal alternating routes, abnormal metabolites increase



Why We Should Know Inborn Errors Of Metabolism?

- Reduce mortality rate
- To prevent irreversible organ damage
- Avoiding long, laborious and expensive diagnostic processes
- Genetic counseling

Why Should We Think Metabolic Disease?

- Metabolic diseases can occur at any age
- History and physical examination!
- Collect and store samples properly prior to emergency treatment.
- Be aware of the important clinical pictures that metabolic diseases should be considered in differential diagnosis.
- * Prioritize and rule out curable metabolic diseases.
- If in doubt, consult your metabolic specialist.

When Should We Think Metabolic Disease?



- Pregnancy history:
 - Mother's health
 - HELLP, AFLP
- Family history:
 - Consanguineous marriage
 - Unexplained death of newborn and infant
 - Similar illness
- Medical history:
 - Recurrent attacks of acidosis, hypoglycemia, acute encephalopathy
 - Intolerance to some foods
- Self-injurious behavior
- Psychiatric symptoms
- Seizure
- Observation of irritability, convulsion, ataxia in childhood diseases after vaccination
- Type of growth retardation:
 - Mental retardation
 - Loss of acquired skills
 - Hypotonia
 - Speech delay

When Should We Think Metabolic Disease?



- **Neonatal period:**

- Feeding difficulties
- Vomiting
- Dehydration
- Sepsis
- Special odor
- Breathing difficulty
- Jaundice
- Convulsion
- Hypotonia
- Lethargy, coma
- Hydrops fetalis
- Facial dysmorphism
- Hepatomegaly
- Cataract
- Sudden death

When Should We Think Metabolic Disease?



- **Infancy and childhood:**

- **Acute and recurrent symptoms:**

- Recurrent vomiting, lethargy, coma, ataxia
 - Rapid breathing
 - Convulsion
 - Encephalopathy

- **Chronic progressive general symptoms**

- Motor and mental retardation, behavioral disorders
 - Hypotonia, hypertonia, opisthotonus
 - Specific smell, myopathy
 - Microcephaly, macrocephaly, hydrocephalus
 - Dysmorphic appearance

When Should We Think Metabolic Disease?

- **Symptoms concerning a specific organ:**

- Cardiomyopathy
- Dysmorphic appearance
- Lens findings, retinal disorders, cataracts
- Organomegaly
- Unexplained liver disease
- Renal symptoms
- Changes in hair, nails and skin
- Skeletal changes



| Homocystinuria | Marfan syndrome |
|--|--|
| Autosomal recessive | Autosomal dominant |
| Intellectual disability | Normal intelligence |
| Ocular lens usually dislocated downward (ectopia lentis) | Ocular lens usually dislocated upward (ectopia lentis) |
| Limited joint mobility | Lax joint (hyperflexibility) |
| Normal aorta | Aortic dilatation |
| Associated with thromboembolism | Not associated with thromboembolism |

Homocystinuria (downward dislocation= low IQ),
Marfan syndrome, upward (upward= normal IQ)

When Should We Think Metabolic Disease?

- Dysmorphic appearance:



I cell



MPS I



MPS VI



MPS IV

When Should We Think Metabolic Disease?

- Dysmorphic appearance:



Zellweger sendromu



Gaucher



Alpha mannosidose



Smith Lemli Opitz Syndrome



Oculocutaneous tyrosinemia (tyrosinemia type 2)

Acrodermatitis enteropathica


Congenital erythropoietic porphyria



Multiple carboxylase deficiency (biotinidase or holocarboxylase synthetase deficiency)



Biotinidase deficiency



Familial homozygous hypercholesterolemia



Prolidase deficiency

When Should We Think Metabolic Disease?




- **Physical examination:**

- Hypotonia, hypertonia
- Coma
- Jaundice
- Growth retardation
- Cataracts, glaucoma, lens subluxation
- Dysmorphism, atypical face, rough facial appearance
- Seborrhea, photosensitive skin lesion
- Skeletal anomaly
- Myopathy, ataxia
- Thromboembolic event, gangrene
- Apnea, respiratory distress

When Should We Think Metabolic Disease?



- Abnormal urine color:
 - Alkaptonuria (black)
 - Porphyruria (red)



Odor

- Musty odor
- Maple syrup odor
- Sweaty feet
- Tom cat urine

- Cabbage odor
- Fish odor

Disease

- Phenylketonuria
- MSUD
- Isovaleric acidemia, GA II
- 3-methylcrotonylglycinuria
- Multiple carboxylase defects
- Tyrosinemia Type 1
- Trimethylaminuria
- Dimethylglycinuria




Laboratory Findings



- Metabolic Acidosis
- Hyperammonaemia
- Respiratory alkalosis
- Hypoglycemia
- Ketosis
- Lactic acidosis
- Pyruvate increase
- Anemia
- Leukopenia
- Thrombocytopenia
- Low urea
- Low creatinine
- Low uric acid
- Elevated uric acid
- Low alkaline phosphatase
- Low cholesterol

CLASSIFICATION OF METABOLIC DISEASES



CLASSIFICATION OF METABOLIC DISEASES



Intoxication type

Energy metabolism disorders

Intracellular metabolism disorders

Intoxication type

- Symptom-free period in which the patient appears healthy at the beginning
- Accumulation of toxic metabolites (hours / months)
- Acute / chronic intoxication picture, recurrent metabolic attacks
- Vomiting, lethargy, coma, liver failure
- Acidosis, ketosis, hyperammonemia, hypoglycemia

Intoxication type

Urea cycle metabolism disorder

Organic acidemias (methylmalonic, propionic, isovaleric acidemia)

Aminoacidopathies (PKU, MSUD, homocystinuria, tyrosinemia)


Fatty acid oxidation defect

Galactosemia

Hereditary fructose intolerance

Energy metabolism disorders

- Impairment in biochemical reactions related to energy production and use
- The four main organs that consume energy



Energy metabolism disorders

- There is no symptom-free period in this type of disease, patients may be symptomatic immediately after birth.
- Diseases in which decreased fasting-tolerance
 - Glucose hemostasis disorder (GSH, gluconeogenesis defects)
 - Situations where alternative substrates cannot be synthesized when glycogen stores are used
 - Fatty acid oxidation defects, ketogenesis, ketolysis defects
- Disturbances in mitochondrial energy metabolism
 - Defects in the PDH complex
 - Respiratory chain defects
- Disturbances in Alternative Energy Sources
 - Creatine Deficiency Syndromes

Energy metabolism disorders

Hipoglycemia

Hipotonia

Sudden infant death syndrome (SIDS)

Myopathy, cardiomyopathy

Circulatory collapse

Lactic acidosis

Cardiac failure

Growth retardation

Intracellular metabolism disorders


- In the synthesis or catabolism of complex molecules metabolic diseases that develop as a result of a disorder
 - Lysosomal diseases
 - Peroxisomal diseases
 - Congenital glycosylation disorders
 - Alpha-1 antitrypsin deficiencies

Intracellular metabolism disorders

- Disturbances in intracellular synthesis and degradation of complex molecules
- Storage without metabolic imbalance
 - Lysosomal storage diseases
 - Gaucher disease
 - Niemann-Pick
 - Mucopolysaccharidoses
- Symptoms are persistent, progressive
- Protein loading, infections do not affect the clinical progress

Mucopolisaccaridosis

- Coarse facial
- Umbilical hernia
- Mental, motor retardation
- Corneal opacity
- Contractures
- Skeletal dysplasia
- Hepatosplenomegaly
- Deafness
- Diagnosis:
 - Dermatan, keratane, heparan sulfates in urine
 - Enzyme activity analysis
 - Genetic



Mucopolisaccharidosis

| MPS type | Subtype and eponyms | Deficient enzyme | Gene (locus) | GAGS involved |
|----------|--|--|---|---|
| MPS I | Hurler (H) Hurler/Scheie (H/S) Scheie (S) | α -L-iduronidase | IDUA (4p16.3) | Dermatan, heparan sulfate |
| MPS II | Hunter A Hunter B | Iduronate sulfatase | IDS (Xq28) | Dermatan, heparan sulfate |
| MPS III | Sanfilippo A Sanfilippo B Sanfilippo C Sanfilippo D | Heparan-N-sulfatase α -N-acetylglucosaminidase Heparan acetyl-CoA: α -glucosaminide N-acetyltransferase N-acetylglucosamine 6-sulfatase | SGSH (17q25.3) NAGLU (17q21) HGSNAT (8p11.1) GNS (12q14) | Heparan sulfate |
| MPS IV | Morquio A Morquio B | Galactose 6-sulfatase β -galactosidase | GALNS (16q24.3) GLB1 (3p21.33) | Keratan, chondroitin sulfate Keratan sulfate |
| MPS VI | Maroteaux-Lamy | Arylsulfatase B | ARSB (5q11-q13) | Dermatan sulfate |
| MPS VII | Sly | β -glucuronidase | GUS (7q21.11) | Dermatan, keratin, chondroitin sulfate |
| MPS IX | | Hyaluronidase 1 | HYAL (3p21.3) | Hyaluronan |

Enzyme Replacement Therapy in Lysosomal storage diseases



| LSDs | Deficient enzyme | Inheritance | FDA approved ERT and Brand name |
|----------------------------------|-----------------------------------|-------------|--|
| MPS I (Hurler syn.) | α -L-iduronidase | Autosomal | Laronidase (Aldurazyme™)/ 2003-FDA, EMA |
| MPS II (Hunter syn.) | Iduronate sulfatase | X-linked | Idursulfase (Elaprase™)/ 2006-FDA; 2007-EMA |
| MPS IV A (Morquio A syn.) | N-acetylgalactosamine 6-sulfatase | Autosomal | Elosulfase Alfa (Vimzim™)/ 2014-FDA |
| MPS VI (Marateaux-Lamy syn.) | N-acetylgalactosamine 4-sulfatase | Autosomal | Galsulfase (Naglazyme™)/ 2005-FDA; 2006-EMA |
| Fabry disease | α -galactosidase | X-linked | Agalsidase α (Fabrazyme™)/ 2001-EMA Agalsidase β (Replagal™)/ 2003-FDA, EMA |
| Pompe disease | α -glucosidase | Autosomal | Agglucosidase (Myozyme™)/ 2006-FDA, EMA Agglucosidase (Lumizyme™)/ 2010-FDA |
| Gaucher disease | β -glucocerebrosidase | Autosomal | Agglucerase (Ceredase™)/ 1991-FDA Imiglucerase (Cerezyme™)/ 1994-FDA; 1997-EMA Velaglucerase (VPRIV™)/ 2010-FDA, EMA Taliglucerase (Elelyso™)/ 2012-FDA |
| Lysosomal acid lipase deficiency | Lysosomal acid lipase | Autosomal | Sebelipase α (Kanuma™)/ 2015-FDA,EMA |

MPS: mucopolysaccharidosis; FDA: U.S. Food and Drug Administration; EMA: European Medical Agency.^{1,5,7}

That's all Folks!